Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of IxCell hUC-MSC-S in convalescent ischemic stroke
CTR20253932Phase 2Active
- Sponsor
- Aisar Biotechnology
- Start
- Oct 2025
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of IxCell in ischemic stroke, sponsored by Aisar Biotechnology. Started Oct 2025; status: active.
02
Drugs
IxCell
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20253932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253932.